Prevalence and Molecular Identification of Human Schistosomiasis
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Molecular phylogenetic and haplotype analysis.
- Who it may be relevant to
- Registry conditions: Schistosomiasis. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Prevalence and Molecular Identification of Human Schistosomiasis With Assessment of Associated Epidemiological Risk Factors in Assiut Governorate, Egypt
Overview
Schistosomiasis remains one of the most important parasitic diseases of public health concern, particularly in developing countries including Egypt. It is caused by a trematode worm (blood flukes) of the genus Schistosoma
Detailed description
Schistosomiasis has been diagnosed in Egypt since pharaonic times (3200 B.C.) by recovering Schistosome eggs and antigens in ancient mummies.In Egypt, Schistosoma mansoni and Schistosoma haematobium have historically been highly endemic, with widespread distribution along the Nile Delta and Valley.(4) Schistosoma haematobium is responsible for urogenital schistosomiasis, with hematuria as its primary manifestation, while Schistosoma mansoni, the prevalent species in Egypt, is causing intestinal schistosomiasis with liver-related sequelae
Interventions
- Diagnostic test Molecular phylogenetic and haplotype analysis
DNA Sequencing and cox1 Gene Analysis of Schistosoma Isolates
Primary outcome measures
- prevalence of human schistosomiasis in the study participants [Time frame: 24 hours]
Eligibility criteria
Inclusion criteria
- Patients aged ≥ 5 years of both sexes attending Assiut Governorate hospitals during the study period.
- Patients clinically suspected of having schistosomiasis (urinary and/or intestinal) or referred for parasitological examination.
- Individuals (or guardians, in case of minors) who provide written informed consent.
- Patients willing to provide the required biological samples (urine and/or stool).
Exclusion criteria
- Patients Received praziquantel within the last 3 months before sample collection
- Patients with incomplete clinical or epidemiological data.
- Patients refusing participation or sample collection.
- Improperly collected, contaminated, or insufficient samples.
- Patients suffering from severe comorbid conditions that may interfere with the interpretation of results (e.g., advanced hepatic or renal failure).
- children with congenital urinary or intestinal anomalies.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Other
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT07482215 · PMHS